Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia

/PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug...

Related Keywords

Australia ,Japan ,Philippines ,Shanghai ,China ,United States ,Beijing ,Ping Xiao ,Fujian ,Peking ,Nanjing ,Jiangsu ,Americans ,Filipino ,Japanese ,Henri Doods ,Bayer Ag ,Prnewswire Hope Medicine Inc ,Hope Medicine Inc ,Drug Administration ,Institute Of Molecular Medicine ,College Of Future Technology Peking University ,Investigational New Drug ,Professor Rui Ping Xiao ,Future Technology ,Professor Xiao ,Molecular Medicine ,Peking University ,